Neuroprotection: A versatile approach to combat glaucoma

Naik, Santoshi; Pandey, Abhijeet; Lewis, Shaila; Rao, Bola Sadashiva Satish; Mutalik, Srinivas

doi:10.1016/j.ejphar.2020.173208

Cited by 19 publications

(29 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several compounds were identified with neuroprotective properties in laboratory settings, mostly in rodent models of optic nerve injury, acute ocular hypertension, and experimental hypertensive glaucoma 180,181 . So far, translation of these treatments into the clinical application with proven efficacy failed.…”

Section: Neuroprotection and Neuroregenerationmentioning

confidence: 99%

Looking into the future: Gene and cell therapies for glaucoma

Komàromy

Koehl

Park

2021

Veterinary Ophthalmology

View full text Add to dashboard Cite

Glaucoma is a complex group of optic neuropathies that affects both humans and animals. Intraocular pressure (IOP) elevation is a major risk factor that results in the loss of retinal ganglion cells (RGCs) and their axons. Currently, lowering IOP by medical and surgical methods is the only approved treatment for primary glaucoma, but there is no cure, and vision loss often progresses despite therapy. Recent technologic advances provide us with a better understanding of disease mechanisms and risk factors; this will permit earlier diagnosis of glaucoma and initiation of therapy sooner and more effectively. Gene and cell therapies are well suited to target these mechanisms specifically with the potential to achieve a lasting therapeutic effect. Much progress has been made in laboratory settings to develop these novel therapies for the eye. Gene and cell therapies have already been translated into clinical application for some inherited retinal dystrophies and age‐related macular degeneration (AMD). Except for the intravitreal application of ciliary neurotrophic factor (CNTF) by encapsulated cell technology for RGC neuroprotection, there has been no other clinical translation of gene and cell therapies for glaucoma so far. Possible application of gene and cell therapies consists of long‐term IOP control via increased aqueous humor drainage, including inhibition of fibrosis following filtration surgery, RGC neuroprotection and neuroregeneration, modification of ocular biomechanics for improved IOP tolerance, and inhibition of inflammation and neovascularization to prevent the development of some forms of secondary glaucoma.

show abstract

Section: Neuroprotection and Neuroregenerationmentioning

confidence: 99%

Looking into the future: Gene and cell therapies for glaucoma

Komàromy

Koehl

Park

2021

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…To overcome this obstacle, rho kinases inhibitors therapies have been introduced, with some side effects reduction and quite few improvements in RGCs survival [ 143 ]. Unluckily, these therapies are not always effective and when they fail the only two alternative approaches are much more invasive and rely either on laser therapy or surgical interventions [ 144 ]. Both argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) or micropulse laser trabeculoplasty (MLT) aim to open the space at the trabecular meshwork [ 145 ].…”

Section: Glaucomamentioning

confidence: 99%

Potential Therapeutic Benefit of NAD+ Supplementation for Glaucoma and Age-Related Macular Degeneration

et al. 2020

View full text Add to dashboard Cite

Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous sources of NAD may become a therapeutic standard for the treatment of these conditions.

show abstract

“…The reasons for this phenomenon are not fully understood, but likely include oxidative stress, excitotoxicity caused by disproportionate excitatory amino acid release, such as glutamate and aspartate, excessive intracellular calcium, neurotrophin deprivation, inflammation, and reactive gliosis. [2][3][4][9][10][11] In order to optimize treatment outcome and limit, or even prevent, further loss of neurons and eyesight, these complicating factors need to be addressed in addition to the treatment of primary underlying disease mechanisms. Like other mammalian central nervous system (CNS) neurons, retinal neurons do not regenerate and cannot be replaced with the currently available technologies, supporting the need for effective neuroprotection.…”

Section: Introductionmentioning

confidence: 99%

“…15,16 Neuroprotection is defined as the alteration of neurons and/or their environment to improve their survival and function in environments that are deleterious to their health. 9 In general, the inclusion of neuroprotective strategies in the management of degenerative retinal and optic nerve diseases is independent of the treatment of primary disease mechanisms and provides a more comprehensive therapeutic approach. 17 Several neuroprotective strategies have been successfully developed and tested in the laboratory, most importantly in rodent models of retinal and optic nerve disease; however, proof of clinical efficacy in human and companion animal patients has been limited or mixed.…”

Section: Introductionmentioning

confidence: 99%

Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases

Hopper

Montiani‐Ferreira

Pereira³

et al. 2021

Veterinary Ophthalmology

View full text Add to dashboard Cite

Objective: To investigate veterinary ophthalmologists' use of presumed neuroprotective therapies for degenerative retinal and optic nerve diseases in dogs.Procedures: An online survey was sent to 663 board-certified veterinary ophthalmologists who were Diplomates of the American College of Veterinary Ophthalmologists (ACVO), Asian College of Veterinary Ophthalmologists (AiCVO), Latin American College of Veterinary Ophthalmologists (Colegio Latinoamericano de Oftalmólogos Veterinarios, CLOVE), or European College of Veterinary Ophthalmologists (ECVO). The survey was created using Qualtrics® software and focused on the prescription of presumed neuroprotective treatments for canine glaucoma, sudden acquired retinal degeneration syndrome (SARDS), progressive retinal atrophy (PRA), and retinal detachment (RD). Results: A total of 165 completed surveys were received, representing an overall response rate of 25%, which was comparable across the four specialty colleges. Of all respondents, 140/165 (85%) prescribed some form of presumed neuroprotective therapies at least once in the last five years: 114/165 (69%) for glaucoma, 51/165 (31%) for SARDS, 116/165 (70%) for PRA, and 50/165 (30%) for RD. The three most recommended neuroprotective reagents were the commercial Ocu-GLO™ Vision Supplement for animals, amlodipine, and human eye supplements. Conclusions: Despite lack of published clinical efficacy data, the majority of surveyed board-certified veterinary ophthalmologists previously prescribed a presumed neuroprotective therapy at least once in the last five years in dogs with degenerative retinal and optic nerve diseases.

show abstract

Neuroprotection: A versatile approach to combat glaucoma

Cited by 19 publications

References 137 publications

Looking into the future: Gene and cell therapies for glaucoma

Looking into the future: Gene and cell therapies for glaucoma

Potential Therapeutic Benefit of NAD+ Supplementation for Glaucoma and Age-Related Macular Degeneration

Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases

Contact Info

Product

Resources

About